Dr. Clay Siegall is an outstanding oncologist, well known for his efforts to transform the field of cancer drugs and therapies development through his firm, Seattle Genetics. He founded the company in 1998, and he has since led it to record massive growth and record profits. He has also led his team in creating FDA-approved ADCs, which have garnered multiple partnerships with major drug industry drivers, such as Bayer and Pfizer among others. Siegall is focused on creating new and more effective ways of treating cancer.
How It Began
In his university days studying zoology, Clay Siegall developed an interest in medicine, technology and a desire to restore health, particularly to cancer patients. He also encountered the disease with one of his family members and was not satisfied with the treatment that he was receiving, which caused anemia at some point. He became aware of alternative ways of treatment, such as radical surgery and amputation, which made him think that there must be a better way. He was also looking at owning patents instead of working for someone else, and that’s how he got the idea for Seattle Genetics.
The firm has been generating some revenue from their first approved drug, ADCETRIS. Clay notes that getting approval for any drug is an expensive affair and that’s why his firm has adopted other ways of making income, such as entering into production partnerships and licensing the company’s drug processes and technologies. The company acquired very qualified sales person who pushed the drug and saw the signing of their first client. Since then the drug has become a household name, and it practically sells itself though he highly regards his team. His hardworking nature is what drives his success and that of his business.
About Clay Siegall
From the year 1988 to 1991, Dr. Clay Siegall was a member of the National Cancer Institute and the National Institute of Health after which he joined Bristol-Myers Squibb Institute. He attended the celebrated University of Maryland and the eminent George Washington University where he studied zoology and genetics respectively.
Dr. Clay Siegall holds other roles as a board of director member for Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and Washington Roundtable. He has patented over 15 drug development technologies.